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upon which the premium of the plan was based, but a
mechanism to permit consideration of other costlier drugs, which
become cost-effective because they specifically address a more
serious clinical situation.
Applications for non-formulary drugs for patients with mild
or newly diagnosed conditions not included in this definition
will not be accepted, consistent with good and cost-effective
clinical practice.
E Gottlich 
Principal Clinical Specialist
Discovery Health
1. Rayner B. Prescribed minimum benefits or minimum prescribed benefits? S Afr Med J 2004; 94:
623-624.
Brian Rayner replies: I would like to thank Dr Gottlich,
Principal Clinical Specialist, Discovery Health for replying to my
article in the Journal. It is a very sad state of affairs that I had to
place my viewpoint in the Journal to get his attention. Over the
past year I have made several motivations to Discovery Health
and I have never received a reply. This complete lack of
recognition of my (and other doctors’) professional standing is
certainly cause for umbrage.
It seems that Dr Gottlich has also missed several key points in
my article. Firstly, as I clearly stated, I am in favour of the use of
affordable and cost-effective medication for hypertension. I also
have no issue with the use of formularies by medical funders
provided that these are based on recognised clinical standards,
preferably the Southern African Guidelines for Hypertention.1 I
see many patients who are members of Discovery Health, and I
can usually manage their hypertention effectively with the use of
their formulary. Yet as a prominent specialist in this field I am
referred complicated hypertensive patients, who just cannot be
managed within the confines of a very basic formulary or
algorithm.
Secondly, Dr Gottlich is incorrect in stating that patients on
prescribed minimum benefits (PMBs) are only entitled to receive
benefits within the Council for Medical Schemes algorithm, or
Discovery Health formulary. Apart from the fact that the PMBs
constitute the standard care to be afforded to members on the
lowest options, and should not be construed as to become the
maximum, the regulations to the Medical Schemes Act of 1998
(Act No. 131 of 1998) clearly state that ‘. . . provision must be
made for appropriate exceptions where the protocol has been
ineffective or causes or would cause harm to the beneficiary
without penalty to the beneficiary. Furthermore if managed health
care entails use of a formulary or restricted list of drugs such
formulary or restricted list must be developed on the basis of
evidence-based medicine taking into account considerations of
cost-effectiveness and affordability, but must make provision for
appropriate substitution of drugs where a formulary drug has
been ineffective or causes or would cause harm to the beneficiary
without penalty to the beneficiary.’
Thirdly, despite protestations, Discovery Health’s compliance
with the hypertension algorithm is selective. It does not allow the
use of angiotensin receptor blockers in patients with type 2
diabetes and microalbuminuria.
Fourthly, regarding the specific patient who prompted my
communication, it is simply a distortion of the truth to state that
Discovery Health changed their mind on review. This occurred
because I lodged a formal complaint with the Council for
Medical Schemes. Sadly, most patients are unaware of their rights
in this regard. This leaves medical practitioners with no option
but to face time-consuming administrative hurdles, including
difficulty in accessing clinical peers in such cases as the one I
described.
1. FJ Milne and VJ Pinkney-Atkinson for the Southern African Hypertension Society Hypertension
Guideline Working Groups 2000 and 2003. Hypertension guideline 2003 update.  S Afr Med J
2004; 94: Part 2, 209-226.
A tale of two industries
To the Editor: On 30 September, Merck voluntarily stopped
selling its arthritis drug rofecoxib (Vioxx) because new data
found that it doubled patients’ risk of heart attack and stroke.
Vioxx was a bestseller, with global annual sales of R16 billion.
Merck could have continued marketing the drug with
appropriate health warnings, but it decided that it was in the best
interests of its patients to withdraw the medication.
Cigarettes, too, double the risk of heart attacks and stroke. In
addition, smokers are 10 times more likely to die of emphysema
or lung cancer. In fact, smoking is linked to 50 diseases, from
blindness to foot amputations.
So what have cigarette manufacturers done to protect their
customers? Did they warn of the dangers and prepare to phase
out cigarette sales? Well, no. Actually they did exactly the
opposite. They hid the facts and tried to sell more cigarettes.
The US Justice Department has charged the companies with
behaving like an organised crime syndicate. In a current court
case, US cigarette makers are accused of conspiracy to defraud
consumers by denying the dangers of smoking and passive
smoking; of sponsoring junk science by funding sympathetic
scientists to carry out research to cloud the issue; of manipulating
nicotine levels to keep smokers hooked; of intentionally
marketing to youth; of promoting low-tar cigarettes as less
harmful knowing that this is not true; and of destroying and
concealing documents to hide their illegal activities.
The truth is that the cigarette companies have lost touch with
reality and what is responsible behaviour. British American
Tobacco, for instance, blathers that government proposals for
new picture-based health warnings to better inform the public of
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the dangers of tobacco could cost it ‘hundreds of millions of
rands.’
Once again it puts its own profits above its customers’
welfare. In sharp contrast to Merck, this irresponsible industry
wants to laugh all the way to the bank, while its customers and
their families limp to hospitals and early graves.
Yussuf Saloojee
Executive Director
National Council Against Smoking
PO Box 1242
Houghton
2041
Pruritus ani
To the Editor: I read the short piece in a recent SAMJ1 reporting
on a small clinical trial of capsaicin in the treatment of pruritus
ani. I have never understood the logic of using a counter-irritant
to treat skin lesions. I would expect such topical treatment to
aggravate the lesions.
The report correctly points out that pruritus ani is perpetuated
by, inter alia, irritant chemicals in faeces. Therefore I tell my
patients that they must not use toilet paper, which serves to rub
the faeces into the inflamed peri-anal skin. They must
programme themselves to defecate in the comfort of their own
home, and to use only soap and water thereafter. The vicious
scratch-itch cycle can be broken using 1% hydrocortisone oitment
12-hourly.
This simple management was told to me when a student by
that mainstay of good patient care — an experienced rural
general practitioner. I can assure your readers that it works, at
minimal cost. Very similar management has recently been
promoted in South Africa.2
S A Craven
9 Remington Road
Wynberg
7800
1. A novel and effective treatment for pruritus ani (In Brief). S Afr Med J 2004; 94: 912.
2. Saxe N, Jessop S, Todd G. Handbook of Dermatology for Primary Care. Cape Town: Oxford
University Press, 1997: 162-163.
This book is for people whose lives are touched by
HIV and Aids: those who are 
HIV-positive themselves, and those who are affected
by people who have HIV or Aids.
This third edition has been updated to reflect the
most recent advances in research on the HI virus,
and to address more fully:
• the use of anti-retroviral therapy
• tuberculosis
• sexually transmitted infections
• home-based care
• support for the caregiver 
• care of orphans and other vulnerable children.
It provides knowledge, skills and support for every
aspect of living with HIV/Aids, and will be invaluable to counsellors, nurses,
home-based caregivers, social workers, teachers, doctors, therapists, spiritual
workers, volunteers, as well as to people living with HIV and their loved ones.
Issues addressed include:
• the fundamental facts about HIV/Aids
• principles and strategies for enabling behaviour change
• HIV/Aids and life skills training for schoolchildren
• basic counselling principles and skills
• pre- and post-HIV-test counselling
• counselling in various contexts, including crisis counselling, couple
counselling, and counselling children 
• spiritual and bereavement counselling
• nursing care principles for hospitals, clinics and in the home
• the legal and ethical aspects of HIV/Aids and policy development.
Special attention is paid to women and children’s issues and rights, self-
awareness and attitudes, cross-cultural counselling, and traditional African
beliefs and customs. Practical advice is offered on how to care for people in
health care settings with limited resources, facilities and finances, such as those
found in many clinics and homes in Africa.
About the author:
Professor Alta van Dyk is a psychologist, professional nurse, and HIV/Aids
counsellor and educator. She is a lecturer at the University of South Africa,
where she teaches psychology and courses in HIV/Aids care and counselling.
‘Thank you for addressing and dealing with every issue that manifests with
caring for the HIV/Aids infected person. HIV/Aids Care & Counselling is a MUST
for every care giver, professional or lay.’ Gail Johnson - Nkosi Johnson’s mother
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